Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Michael L, Wang, Wojciech, Jurczak, Mats, Jerkeman, Judith, Trotman, Pier L, Zinzani, David, Belada, Carola, Boccomini, Ian W, Flinn, Pratyush, Giri, Andre, Goy, Paul A, Hamlin, Olivier, Hermine, José-Ángel, Hernández-Rivas, Xiaonan, Hong, Seok Jin, Kim, David, Lewis, Yuko, Mishima, Muhit, Özcan, Guilherme F, Perini, Christopher, Pocock, Yuqin, Song, Stephen E, Spurgeon, John M, Storring, Jan, Walewski, Jun, Zhu, Rui, Qin, Todd, Henninger, Sanjay, Deshpande, Angela, Howes, Steven, Le Gouill, Martin, Dreyling, Joseph C, Gardiner
Publikováno v:
New England Journal of Medicine. 386:2482-2494
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.We randoml
Autor:
Junji Suzumiya, Seok-Goo Cho, Keum Young Ahn, Marek Trneny, Eduardo Yanez Ruiz, Christian Buske, Leslie Popplewell, Jose Mario Mariz, Michinori Ogura, Larry W. Kwak, Olga Samoilova, Tobias F. Menne, Hideyuki Nakazawa, Jin Seok Kim, Edvard Zhavrid, Gayane Tumyan, Nikolai Ilyin, Sunghyun Kim, Sang-Joon Lee, Wojciech Jurczak, Won Seog Kim, Juan-Manuel Sancho, A. Martínez
Publikováno v:
Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
INTRODUCTION: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a s
Autor:
KeumYoung Ahn, Mariana Vasilica, Christian Buske, Rajnish Nagarkar, Edvard Zhavrid, Aliaksandr Prokharau, Sung-Hyun Kim, Juan-Manuel Sancho, Michinori Ogura, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Jin Seok Kim, Sang Joon Lee, Larry W. Kwak
Publikováno v:
Blood Adv
Rituximab biosimilars are a cornerstone of treatment of advanced-stage follicular lymphoma (FL). This double-blind, parallel-group, phase 3 trial randomized (1:1) adults (≥18 years) with stage III to IV indolent B-cell lymphoma, including grades 1
Autor:
Polina Kaplan, Javier de la Serna, Malgorzata Wach, Sean Dolan, Phillip L. Campbell, Jae Hoon Lee, Martin Simkovic, Árpád Illés, Iryna Kraychok, Eric J. Avery, Wojciech Jurczak, Andrzej Pluta, Abraham Jacob, Tomas Kozak, Gerardo Musuraca, Daniel Lysák, Wei Liang, Priti Patel, Cheng Quah, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 38:2849-2861
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). MET
Autor:
Constantine S Tam, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M Brander, Ian W Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen
Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::561e4c262d70c0f906480609b1cc7bfd
https://ruj.uj.edu.pl/xmlui/handle/item/298141
https://ruj.uj.edu.pl/xmlui/handle/item/298141
Autor:
Krzysztof Warzocha, Monika Chełstowska, Wojciech Jurczak, Monika Długosz-Danecka, Bartosz Pula, Agata Malenda, Agnieszka Kołkowska-Leśniak, Agnieszka Końska, Ewa Lech-Marańda, Agnieszka Giza
Publikováno v:
European Journal of Haematology. 104:59-66
Background The standard first-line treatment for primary mediastinal B-cell lymphoma (PMBCL) patients is rituximab-based immunochemotherapy; however, this is not due to the result of randomized clinical trials. Aims We retrospectively investigated 53
Autor:
S. Nasta, Deepa Jagadeesh, Wojciech Jurczak, A. Attinger, Moshe Yair Levy, H. Pylypenko, Marek Trneny, Zhanet Grudeva-Popova, E. Rouits, H. Nauwelaerts, S. Toffanin, M. Dymkowska, D. Rechavi-Robinson, F. J. S. H. Woei-A-Jin, S. Micallef, Marc André
Publikováno v:
Hematological Oncology. 39
Autor:
Aruna Mehra, L. Mongay Soler, Árpád Szomor, Muhit Ozcan, Qingyuan Zhang, Eduardo Yanez, Barrett H. Childs, Jie Jin, P. L. Zinzani, Rinat Galiulin, Florian Hiemeyer, Klaus Geissler, Igor Bondarenko, Ross I. Baker, Toshiki Uchida, Kamal Bouabdallah, Wojciech Jurczak, Anjun Cao, Jifeng Feng, Wei Li, Fangfang Lv, Aryan Hamed, M. Matasar, T. Lin, Mihaela Lazaroiu, Güray Saydam, Katya Sapunarova, Yuankai Shi, Ming-Chung Wang, Marcelo Capra
Publikováno v:
Hematological Oncology. 39
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W
Autor:
Aryan Hamed, Güray Saydam, Muhit Ozcan, Aruna Mehra, Klaus Geissler, Florian Hiemeyer, Yuankai Shi, Toshiki Uchida, Árpád Szomor, Rinat Galiulin, Lidia Mongay Soler, Fangfang Lv, Eduardo Yanez, Igor Bondarenko, Katya Sapunarova, Matthew J. Matasar, Marcelo Capra, Anjun Cao, Jifeng Feng, Pier Luigi Zinzani, Mihaela Lazaroiu, Krimo Bouabdallah, Jie Jin, Wei Li, Qingyuan Zhang, Wojciech Jurczak, T. Lin, Barrett H. Childs, Ming-Chung Wang, Ross Baker
Publikováno v:
The Lancet. Oncology. 22(5)
Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to as